A Billion-Dollar Bet on AI-First Drug Development

What It Covers

Marc Tessier-Lavigne, co-founder and CEO of Xara, explains how the company deploys over $1 billion in funding to apply end-to-end AI across three drug development bottlenecks: target identification, molecular design, and patient stratification, with an initial focus on historically undruggable biological targets.

Key Questions Answered

• •Causal vs. Descriptive Data: Models trained on descriptive data like single-cell RNA sequencing fail at causal prediction tasks at rates no better than a coin toss. Xara generates genome-scale perturbation datasets using PerturbSeq — 20,000-gene perturbations by 20,000-gene readouts across multiple cell types — to train models capable of predicting which genetic changes transition cells from diseased to healthy states.
• •Undruggable Target Strategy: Rather than competing on accessible targets where existing antibody methods like phage display or humanized mouse immunization already perform well, Xara focuses on multipass membrane proteins, GPCRs, ion channels, and agonist antibodies to heteromeric receptors — categories where conventional methods frequently fail, providing pipeline differentiation and the strongest showcase for AI capability.
• •Design-Make-Test Feedback Loop: Xara's X-Design model evaluates approximately one billion antibody designs computationally, filters candidates through a secondary model, then physically synthesizes and tests roughly one million designs in the wet lab annually. Successes and failures feed back into the model, progressively improving hit quality toward leads and eventually development candidates without manual iteration.
• •AI as Biology's Mathematics: Eric Schmidt's framing — that AI is to biology what mathematics is to physics — provides a practical framework for understanding why AI succeeds where equation-based biological modeling failed for decades. Unlike physics, biology has no derivable governing equations, but AI can detect patterns across high-dimensional datasets to build predictive cellular models, making it the correct modeling tool for drug discovery.
• •Bilingual Talent Pipeline: No sufficiently large pool of scientists fluent in both AI and biology currently exists. Xara's near-term solution pairs AI scientists with disease biologists and drug hunters in program-based teams, while building internal AI agents that let each group self-serve in the other's domain. The company anticipates a generation of natively bilingual scientists emerging within ten years from universities and early-career roles.